Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
- About
Alpha Cognition Inc (ACOG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ACOG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -12.67% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 50300 | Beta - | 52 Weeks Range 4.66 - 8.91 | Updated Date 02/15/2025 |
52 Weeks Range 4.66 - 8.91 | Updated Date 02/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE 16.05 | Enterprise Value 95147331 | Price to Sales(TTM) - |
Enterprise Value 95147331 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.57 | Shares Outstanding 6000000 | Shares Floating - |
Shares Outstanding 6000000 | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Alpha Cognition Inc
Company Overview
History and Background
Alpha Cognition Inc. (ACOG) is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases and cognitive impairment. It was founded in 2013 and has been focused on developing proprietary formulations of naturally occurring metabolites to improve cognitive function.
Core Business Areas
- Drug Development: Development of novel therapeutic approaches for Alzheimer's disease and other neurodegenerative conditions.
Leadership and Structure
Alpha Cognition is led by a management team with experience in drug development and commercialization. Details on specific leaders and the detailed organizational chart would need further research.
Top Products and Market Share
Key Offerings
- ALPHA-1062: A proprietary, slow-release formulation of an approved Alzheimer's drug. It targets mild-to-moderate Alzheimeru2019s disease. It is currently in clinical development. Details on market share and number of users is unavailable as it is not yet approved. Competitors include manufacturers of currently approved Alzheimer's drugs (e.g., Aricept, Exelon, Namenda, Aduhelm, Leqembi) and companies developing novel Alzheimer's therapies such as Eli Lilly with Donanemab.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with significant investments in research and development. The Alzheimer's disease market is large and growing due to the aging population.
Positioning
Alpha Cognition aims to develop improved and novel treatments for cognitive decline, targeting specific unmet needs in the Alzheimer's disease space. It competes with larger pharmaceutical companies.
Total Addressable Market (TAM)
The Alzheimer's disease market is projected to reach hundreds of billions of dollars. Alpha Cognition is positioned to capture a segment of this market with its novel formulations, assuming clinical and regulatory success.
Upturn SWOT Analysis
Strengths
- Proprietary drug formulations
- Focus on a significant unmet medical need
- Experienced management team
Weaknesses
- Reliance on successful clinical trials
- Limited financial resources compared to larger competitors
- Not yet any products approved to generate revenue.
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Government funding for Alzheimer's research
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other companies developing Alzheimer's drugs
- Generic drug competition
Competitors and Market Share
Key Competitors
- LLY
- ESAI
- ABBV
Competitive Landscape
Alpha Cognition is a smaller player competing with larger pharmaceutical companies. Its advantage lies in its novel drug formulations and focus on specific unmet needs.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: As a clinical-stage company, historical growth is limited. Growth depends on clinical trial progress.
Future Projections: Future growth depends on the successful development and commercialization of its drug candidates. Analyst estimates would need to be pulled from external sources to analyze future projections.
Recent Initiatives: Recent strategic initiatives likely include advancing ALPHA-1062 through clinical trials and seeking partnerships for further development and commercialization.
Summary
Alpha Cognition is a biopharmaceutical company focusing on therapies for neurodegenerative diseases and cognitive impairment. It relies on the successful development and commercialization of ALPHA-1062 for growth. It is still in the early stage, thus has yet to make any profits. Investors should keep an eye out for clinical trial results and regulatory progress, but it does face significant competition from pharmaceutical giants.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
Sources and Disclaimers
Data Sources:
- Company website
- Company filings
- Industry reports
- Analyst estimates
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alpha Cognition Inc
Exchange NASDAQ | Headquaters Vancouver, BC, Canada | ||
IPO Launch date 2024-11-12 | CEO & Director Mr. Michael E. McFadden B.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.alphacognition.com |
Full time employees - | Website https://www.alphacognition.com | ||
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.